<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=319805651697215&amp;ev=PageView&amp;noscript=1">

What Biopharma Needs to Know About CAR-T Cancer Therapies

Mon, Apr 27, 2015

clinics_research_smCAR-T is a therapy in which T-cells are removed from a patient’s body and re-engineered to make them into deadly cancer-seeking cells, which then target a particular cancer and destroy it.  CAR-T has become such a talked-about therapy that many people might assume that it’s commercially available. In fact, CAR-T has not been approved for clinical use by any regulatory agency, but oncology researchers are hard at work attempting to take early-stage studies and turn them into viable, reproducible clinical therapies. Cryoport is uniquely positioned to support the development of these life-saving treatments by transporting these cell-based therapies between reearch centers and to the point of care.

>> Click here to read more about CAR-T Cancer Therapies

Tags: frozen shipping solution, Biopharmaceutical Cold Chain, CAR-T cells,, cancer therapies